肿瘤细胞治疗研究
ALL SOURCES
Phase 1 Study of Anito-cel, a d-Domain BCMA CAR T Cell for Refractory or Recurrent Myeloma.
Anito-cel 治疗在重度经治的复发/难治性多发性骨髓瘤患者中导致了高缓解率。3 级或更高级别的细胞因子释放综合征和 ICANS 罕见。（由 Arcellx 和 Kite，一家吉利德公司资助；ClinicalTrials.gov 注册号：NCT04155749。）
In vivo CAR T-cell therapy: determinants of response and durability.
Persistence of mucosal CAR-T cells and inflammatory remodeling in enterocolitis associated with BCMA CAR-T cell therapy.
Gene regulatory elements determine efficacy of BCMA-targeted CAR-T cell products.
Next-generation antibody-based therapeutics in cancer: antibody-drug conjugates bispecific antibodies across hematologic malignancies and solid tumors
A novel triple-knockout allogeneic BCMA CAR T-cell therapy (CT0590) for multiple myeloma: preclinical and phase 1 study.
Arlocabtagene autoleucel: a GPRC5D-targeted CAR T-cell therapy for heavily pretreated relapsed/refractory multiple myeloma.
A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenali
这是一项 III 期、随机的注册临床试验，评估细胞治疗用于多发性骨髓瘤的疗效与安全性。研究设计：随机、2 个分组。当前状态：进行中（不再招募）。计划入组 743 例。试验地点：美国 · 旧金山、纽黑文、迈阿密、奥兰多（共 136 个中心）。登记号：NCT04923893。
Ikaros degradation by mezigdomide reduces T-cell dysfunction and improves the efficacy of antimyeloma T-cell therapies.
Lesion-level PET/CT analysis to identify predictors of progression after BCMA CAR T-cell therapy in multiple myeloma.
MEMBER ACCOUNT
登录成功会直接打开下一页。
